Most of what this site counts is an absence — a dose not stated, a state list not published, a fee not totaled. That habit has a failure mode: a publication that only measures failures ends up describing its own appetite rather than the market. So here is something this market largely gets right, against the silences counted in nobody says what happens at a higher dose.
What it gets right
Of the 419 sellers offering more than one molecule-and-format combination, 357 publish a price against every combination they list. That is 85% of them, and it is a better record than this category manages on almost any other disclosure.
The remaining 62 split into two groups. 50 list something they do not price — typically a single product, and at the extreme 5. A further 12 list several products and price none of them at all.
Why it is easier than the rest
Pricing what you list is the disclosure with the lowest cost to the seller. A price is already the thing the page exists to communicate, and leaving a product listed but unpriced creates friction for the buyer and the seller alike.
Compare that with a dose ladder, which advertises that the headline figure will rise, or a state list, which disqualifies readers on sight. Those disclosures cost something, and the counts reflect it — which is the pattern in nobody says what happens at a higher dose and in where choice runs out.
What the exceptions look like
A product listed beside a blank is a specific and avoidable annoyance: it invites a buyer to start an intake to discover a number. That is a different failure from pricing behind a consultation as a stated policy, and this count cannot distinguish the two.
Where a seller prices nothing it lists, the reviews on this site say so individually rather than the census guessing at why. The broader question of how much published pricing is a real rate rather than an offer is in the gap between what is shown and what is billed, and what a year of any of it costs is in what a GLP-1 actually costs.